PDS Biotech Announces Presentation of Preliminary Results from Phase 2 Study of IL-12 Tumor Targeted Immunocytokine (PDS01ADC) in 3rd Line Metastatic Castration Resistant Prostate Cancer by the NCI

Core Insights - The study led by the National Cancer Institute (NCI) demonstrated a median progression-free survival (PFS) of 9.6 months for the investigational drug PDS01ADC in patients with metastatic castration-resistant prostate cancer (mCRPC) [1][2] - The combination therapy showed a median PSA decline of 40%, with 6 out of 16 patients achieving more than a 50% decline [2] - PDS Biotech aims to advance PDS01ADC as a key component of its immuno-oncology pipeline, reinforcing its potential to enhance existing therapies across various solid tumor types [3] Company Overview - PDS Biotechnology Corporation is a late-stage immunotherapy company focused on transforming immune responses to cancer [4] - The company has initiated a pivotal clinical trial for its lead program targeting advanced HPV16-positive head and neck squamous cell cancers [4] - PDS Biotech's lead investigational therapy, PDS0101 (Versamune HPV), is being developed in combination with standard immune checkpoint inhibitors and PDS01ADC [4]